Compare
Lilly (Eli) vs Pacira BioSciences (LLY vs PCRX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Lilly (Eli) (LLY) returned +46.2% and Pacira BioSciences (PCRX) +66.7%; so far this year the figures are +26.0% and +40.8%.
Lilly (Eli) is the larger company by market value, about 872.4 times the size of Pacira BioSciences.
On trailing earnings, LLY trades at 43.9 times and PCRX at 39.2 times.
Revenue grew +45.5% at LLY and +3.7% at PCRX over the last year.
LLY yields 0.49%. PCRX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| LLY | PCRX | |
|---|---|---|
| Price | $1,354.00 | $36.43 |
| 1-day | -0.79% | +0.03% |
| YTD | +25.99% | +40.77% |
| 1 year | +46.25% | +66.73% |
| 3 years | +144.20% | +28.68% |
| Market cap | $1.27T | $1.5B |
| P/E | 43.9 | 39.2 |
| P/S | 14.73 | 1.97 |
| P/B | 31.63 | 2.05 |
| Revenue growth | +45.50% | +3.70% |
| EPS growth | +50.70% | +102.20% |
| Gross margin % | 83.6 | 78.7 |
| Net margin % | 31.9 | 5.1 |
| ROE % | 68.5 | 5.3 |
| Debt / equity | 1.23 | 0.41 |
| FCF yield % | 2.4 | 11.6 |
| Dividend yield % | 0.49 | — |
| Beta | 0.29 | 0.12 |
| RSI (14) | 61.1 | 83.2 |
| Technical rating |